Replies to post #297406 on Avid Bioservices Inc (CDMO)

[cjgaddy]

With PerkinElmer emerging in ASCO’2017 as a PPHM-Collaborator for The Biomarkers Project, a smart friend jiggled my mind with this possibility: PerkinElmer, Our Exosomes Partner?? I think it makes perfect sense. PKI's ($6.8B MktCap) big area in Health is Diagnostics...

PerkinElmer Introduction… "Diagnose & Treat Disease Earlier"
2013 Vid(1:28):

Like...
http://www.perkinelmer.com/corporate/company/innovation/index.html
=>"Phenoptics and Vectra 3"

= = = = = = = = = = = = = = = = = = = = = = = = =
Jun2-6: ASCO 2017, Chicago https://am.asco.org See: http://tinyurl.com/kkpqvra
PPHM Exhibiting – booth #13124 (next to Moffitt CC)
6-3-17 1:15-4:45pm, #11603, “Prelim. Correlative Analysis of PD-L1 Expression from the Sunrise Study” (Sunrise Biomarker #4)
...11 Authors: LEAD: Nikoletta Lea Kallinteris (PPHM); SENIOR: Cliff Hoyt (PerkinElmer, "Technology Strategist")
------PERKIN-ELMER/Cliff Hoyt NOTES:
**Nov2016: “Mr. Hoyt is a Technology Strategist in the area of oncology, helping to identify clinical opportunities that can be addressed through new technologies & capabilities. This includes forming collaborations & partnerships with academic & industrial institutions.”
http://www.sciencemag.org/custom-publishing/webinars/multiplexed-immunohistochemistry-illuminating-tumor-microenvironment
**Interesting: 5-1-15/1hr. Webinar Video: Clifford Hoyt (PerkinElmer) & Bernard Fox (Providence CC, Portland) - “Cancer immunology: Charting The Course Forward For Immunoprofiling” (Dr. Hoyt speaks at 31:30)

= = = = = = = = = = = = = = = = = = = = = = = = = =
PPHM's EXOSOME-BASED (PS Positive) CANCER DETECTION & MONITORING TECHNOLOGY ("Liquid Biopsy")
...Excellent Exosome (aka microparticles, microvesicles) info: http://www.exosome-rna.com
2-9-17/PR: PS+ Exosomes Proof-of-Concept Data (N=44, Ovarian, Dr. Alan Schroit/UTSW etal) Published 1-22-17 in OncoTarget http://tinyurl.com/jhv57ua
...Data (blinded plasma from 34 O.C. pts & 10 healthy subjects) supports the “high diagnostic power” of PS+ Exosomes in Ovarian Malignancies.
...Dr. Stephen Worsley (VP/BusDev): “...we believe this has potential applications in several solid tumors beyond ovarian cancer. With that in mind, we look forward to aligning with a partner to help explore the potential of this promising technology."
...PPHM’s PS Exosomes platform advantages outlined: UTSW/website and World Patent #WO/2016/201064: http://tinyurl.com/zbwr7cc
7-14-16: Peregrine Licenses Exosome-based technology from UTSW (Inventors: Alan Schroit/Philip Thorpe) http://tinyurl.com/zszd4fj
...“relates to assays that are able to detect small amts of PS+ Exosomes in a patient's blood sample as a way to detect cancer at a very early stage of development.”
...Dr. Jeff Hutchins (VP/PreclinRES): "Once we have successfully validated this assay, we plan to establish proof-of-concept through an efficient preclinical & clinical testing pgm. We have no intention of conducting further development work beyond the proof-of-concept stage. Rather, we expect to initiate partnering discussions for commercialization of this pgm in 2017."

=========================
NOTE: 4 Known Sunrise Biomarkers thru 5-2017(ASCO): B2GPI, Complement+IL10, IFN-y, PD-L1 Expr.